Showing 1 - 3 results of 3 for search 'Pakes Gary E', query time: 0.03s Refine Results
  1. 1
    Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

    Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens by Pobiner Bonnie F, Liao Qiming, Tashima Karen T, Berger Daniel S, Cohen Calvin J, Swindells Susan, Snidow Jerry W, Pakes Gary E, Hernandez Jaime E

    Published 2005-04-01
    Get full text
    Article
  2. 2
    Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

    Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT by Ross Lisa L, Liao Qiming, Fischl Margaret A, DeJesus Edwin, Weinberg Winkler G, Smith Kimberly Y, Pakes Gary E, Pappa Keith A, Lancaster C Tracey

    Published 2008-03-01
    Get full text
    Article
  3. 3
    Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

    Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment by Snidow Jerry W, Wakeford John H, Williams Vanessa C, Olliffe Jeffrey F, Rodriguez Allan, DeJesus Edwin, Sension Michael G, Keiser Philip H, Shachoy-Clark Anne D, Fleming Julie W, Pakes Gary E, Hernandez Jaime E

    Published 2005-01-01
    Get full text
    Article

Search Tools: